alexa Antibody array|Proteomics|Melanoma|FKBP51 Paradigm
ISSN: 0974-276X
Journal of Proteomics & Bioinformatics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Role for Proteomics in Identifying Targets for Radiosensitizing Strategies in Melanoma: The FKBP51 Paradigm

Anna D’Angelillo1,2, Roberto Pacelli2,3, Rosanna Martinelli4, Paolo D’Arrigo1, Stefania Staibano2, Raffella Avellino5, Luigi Sivero6, Rita Bisogni1 and Simona Romano1*

1Department of Molecular Medicine and Medical Biotechnologies, Federico II University, Naples, Italy

2Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy

3Institute of Biostructures e Bioimaging C.N.R, Naples, Italy

4Department of Medicine and Surgery, University of Salerno, Italy

5 Pineta Grande Hospital, Castelvolturno, Italy

6Department of Clinical Medicine and Surgery, University Federico II of Naples, Italy

*Corresponding Author:
Simona Romano, PhD
Department of Molecular Medicine and Medical Biotechnologies
Federico II University, via Pansini, 5-80131-Naples, Italy
Tel: +39/0817463123
Fax: +39/0817463205
E-mail: [email protected]; [email protected]

Received Date: May 27, 2014; Accepted Date: July 28, 2014; Published Date: August 01, 2014

Citation: D’Angelillo A, Pacelli R, Martinelli R, D’Arrigo P, Staibano S, et al.(2014) A Role for Proteomics in Identifying Targets for Radiosensitizing Strategies in Melanoma: The FKBP51 Paradigm. J Proteomics Bioinform7: 240-247. doi: 10.4172/jpb.1000325

Copyright: © 2014 D’Angelillo A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Journal of Proteomics & Bioinformatics


The treatment of metastatic melanoma is challenging and in the vast majority of cases unsuccessful. Melanoma cells are resistant to most standard therapeutics. We have recently demonstrated that FKBP51 regulates melanoma response to ionizing radiation (IR). To find out molecular targets for radiosensitizing strategies to apply in this neoplasm, we investigated the changes of protein profiles in irradiated melanoma depleted or not of FKBP51, by protein microarray approach. Among the multiple molecules that were found modulated in our cell model, the decrease of several pPKC isoforms in the FKBP51-depleted (IR-sensitive) melanoma appeared to us particularly interesting, because PKC is involved in radiation response. Therefore, PKC was chosen for further investigation. After validating by western blot proteomics results, we found that targeting PKC, with the pan PKC inhibitor LY317615 or enzastaurin, significantly enhanced IR-induced cell death. Most interestingly, enzastaurin combined with IR appeared to be effective in eliminating a subset of melanoma cells expressing a stemness marker. Our study highlighted a role for proteomics in finding useful targets to overcome melanoma resistance, and suggested a combination treatment, which deserves to be investigated in a clinical setting.


Melanoma; PKC; Enzastaurin; Ionizing radiation


Melanoma was diagnosed in about 100.000 and killed 22.000 people in Europe in 2012 [1]. Although representing about the 3% of all diagnosed skin cancer, melanoma accounts for the 65% of deaths due to skin cancer [2]. Radiation therapy (RT) is a useful component of the therapeutic armamentarium for malignant melanoma, and may be indicated in about a fourth of patients bearing the disease [3]. In fact, RT can ameliorate the local control of locally advanced surgically resected melanoma and to palliate symptoms in the metastatic patients, sometimes slowing the progression of the disease with possible prolongation of survival [4]. However, the benefits from radiotherapy and cytotoxic drugs are limited because of the inherent resistance of melanoma. The definition of the molecular mechanisms underlying the phenomenon of cellular resistance to cytotoxic agents may be of help in the process of designing more effective treatments for melanoma.

In a previous work, we provided evidence that targeting of FK506 binding protein 51 (FKBP51) with siRNA determined a significant apoptosis sensitizing effect of irradiated melanoma [5]. Our studies have highlighted a relevant role for FKBP51 in melanoma resistance to genotoxic agents [5-7]. To find out molecular targets for radiosensitizing strategies of melanoma, we investigated the changes of protein profiles in irradiated melanoma depleted or not of FKBP51, by protein microarray approach. Among the multiple molecules that were found modulated in our cell model, the decrease of several pPKC isoforms in the FKBP51-depleted (IR-sensitive) melanoma appeared to us particularly interesting. PKC isozymes are serine/threonine kinases that have been involved in multiple self-reinforcing oncogenic loops in melanoma [8]. The phosphorylation usually triggers a change in the state of activity of the target molecule, which leads to further changes in cellular functions. PKCs activate a range of kinases, including phospholipase C, the phosphatidylinositol 3-kinase, mitogen activated protein-kinases cascade and G-proteins coupled receptors [9]. PKC is one of the earliest responders to IR and inhibition of PKC activity increased the cell killing by IR [10-12].

The decrease of pPKC in IR-sensitive melanoma prompted us to investigate whether a PKC inhibiting agent, namely enzastaurin, could overcome IR resistance, in melanoma. Enzastaurin is an ATP-competitive, PKC-β selective small-molecule inhibitor, at low concentrations (nanomolar), but able to impair the activity of multiple PKC isozymes at higher concentrations that are widely reached or surpassed in clinical trials [13]. In a previous work, we showed the efficacy of this drug in sensitizing melanoma to cell death induced by genotoxic stress [14]. Using combination index analyses [14], we found that enzastaurin and doxorubicin exerted synergism or additive effect on melanoma apoptosis. On the basis of this observation, and after confirming by western blot that FKBP51 downmodulation resulted in a reduced phosphorylation of PKC, we employed enzastaurin in association with IR and measured cell death in a melanoma in vitro model. Our finding show that enzastaurin significantly increased melanoma IR-induced cell death. In addition, we provide data in support of a role for enzastaurin, combined with IR, in eliminating a subset of melanoma cells expressing a stemness marker.

Materials and Methods

Cell culture and reagents

The melanoma cell line SAN [5] was established from a patient’s tumour lymph nodal metastasis and was provided by Dr Gabriella Zupi (Experimental Preclinic Laboratory, Regina Elena Institute for Cancer Research, Roma, Italy). Cells were cultured in RPMI (Roswell Park Memorial Institute) 1640 medium (Lonza, Basel, Switzerland) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Lonza), 200 μM glutamine (Lonza) and 100 U/ml penicillin– streptomycin (Lonza) at 37°C in 5% CO2 humidified atmosphere. The melanoma cell line G361, derived from a primary tumour, was cultured in McCoy’s modified medium (Sigma-Aldrich, Saint Louis, MO, USA) supplemented with 10% heat-inactivated FBS, 200 μM glutamine and 100 U/ml penicillin-streptomycin at 37°C in 5% CO2 humidified atmosphere [5]. The melanoma cell line A375, derived from a metastatic tumour, was cultured in Dulbecco’s modified eagle’s medium (Lonza) supplemented with 15% heat-inactivated FBS, 200 mM glutamine and 100 U/ml penicillin-streptomycin at 37°C in 5% CO2 humidified atmosphere [15]. Enzastaurin (LY317615) was purchased from Biosciences (San Jose, CA USA).

Antibody array

SAN melanoma cells were transfected as previously described [5,15], with a specific small interfering (si) RNA for FKBP51 or a non silencing (NS) RNA as a control. After 24 h from transfection, cells were irradiated with 6MV X-ray of the linear accelerator at the dose of 4Gy. Six hours later cells were harvested for protein extraction. Lysates were extracted in RIPA modified buffer [16] and each experimental point was labeled with a different cyanine (3 or 5) and used for the XPRESS Panorama Antibody Array Kit (Sigma). This antibody array contains 725 different antibodies each spotted in duplicate on nitrocellulosecoated glass slides useful to detect a wide variety of proteins, which can be categorized in seven subgroups, including apoptotic, cell cycle, nuclear signaling, stress, calcium-associated, cytoskeleton and signal transduction based on biological functions (see more at: Pathway analysis was used to identify differences in protein profile changes between FKBP51 silenced, or not, cells: top ten most significant pathways from GeneGo MetaC analysis following proteins selection with GeneSpring 10.1 software. The identified deregulated proteins by protein microarray were converted into gene symbols and uploaded into MetaCore version 6.7 (GeneGo, MI, USA) for biological network building. The “GeneGo Pathway Maps” algorithms were used to map the uploaded proteins. The relevant pathway maps were then prioritized based on their statistical significance with respect to the uploaded data sets.

Western blot

Whole cell lysates were homogenized in modified RIPA buffer and assayed in Western blot as described [5,15]. Primary antibodies against Phospho-PKC (pan-γ-Thr514, rabbit polyclonal; Cell Signaling, Danvers, USA), FKBP51 (F-13; goat polyclonal; Santa Cruz Biotechnology, CA, USA); PKC-PAN (rabbit polyclonal, Sigma) were used at the dilution of 1:1000. GAPDH (rabbit polyclonal; Cell Signaling, Danvers, USA) was used at the concentration of 1:3000.

Analysis of apoptosis

Analysis of apoptosis was conducted using annexin-V staining [5]. Cells were stimulated with enzastaurin at the doses of 0.6 and 2 μM and subjected or not to IR (4 Gy). After 48 h, cells were harvested, washed in PBS and treated as previously described [5]. Caspase 3 was determined using the Carboxyfluorescein Fluorochrome Inhibitor of Caspases Assay (FLICA) Kits (B-Bridge International, San Jose, USA) according to the instructions of the manufacturer. Cells are permeable to the fluorochrome inhibitor that binds covalently to the activated caspase. Briefly, 6 h after exposure to IR and/or enzastaurin, melanoma cells were harvested and resuspended in 300 μl PBS containing FLICA reagent, for 1 h at 37°C in a 5% CO2 atmosphere, in the dark. During the incubation, cells were gently resuspended twice to ensure an optimal distribution of the FLICA reagent among all cells. Then, the cells were washed twice in wash buffer by centrifugation at 400 g for 5 min, resuspended in 300-400 μl of PBS, and analyzed by flow cytometry. The green fluorescent signal was a direct measure of the number of cells with active caspases [14].


Melanoma cells were treated with or without enzastaurin at the dose of 2 μM and exposed, or not, to 4 Gy IR. After 72 h, cells were harvested, ABCG2 expression was measured using the mouse monoclonal antibody anti-ABCG2-PE (R&D Systems, Minneapolis, MN, USA) and analyzed by flow cytometry, as described [5,15]. Total RNA was isolated from cells using Trizol (Invitrogen, Carlsbad, CA, USA) and from paraffinized tissues using the High Pure RNA Paraffin Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions.


Total RNA was isolated from cells using Trizol (Invitrogen, Carlsbad, CA, USA) and 1 μg of each RNA was used for cDNA synthesis with iScript Reverse Transcriptase (Bio-Rad, Hercules, CA, USA). Gene expression was quantified by quantitative (Q) PCR using SsoAdvanced Universal qPCR Supermix (Bio-Rad) and specific QPCR primers for the relative quantitation of the transcripts, performed using co-amplified ribosomal GAPDH as an internal control for normalization:

QuantiTect primers for ABCG2 (QT00073206: NM_0048271100 e 1200 bp)













Statistical analysis

The statistical significance of differences between means was estimated using Student’s t-test. Values of P < 0.05 were considered statistically significant.


FKBP51 knockdown decreases levels of active PKC

Melanoma cell depleted of FKBP51 is highly sensitive to IR [5]. We investigated changes in protein profiles in irradiated melanoma depleted or not of FKBP51, by protein microarray approach. Proteins differentially expressed in the FKBP51 silenced melanoma cells were primarily involved in the regulation of apoptosis (p=1.16×10-11), cytoskeleton remodeling (p=4.11×10-10) and EGFR signaling (p=1.5×10-8). A relevant map is shown in the Figure 1. Proteins on the map are represented by different symbols corresponding to the functional class of the protein reported in the legend. Red and blue thermometers show increased and decreased expression, respectively, in FKBP51 depleted cells. The top ten most significant pathways, which were ranked based upon p-value, are also shown in Figure 1. The map highlights that several pPKC isoforms are downregulated in FKBP51 depleted melanoma. To confirm the effect of FKBP51 in regulation of PKC activation, we measured by western blot the levels of phosphoPKC, using a pan PKC phospho-antibody, in SAN and G361 melanoma cell lines, derived from metastatic and primary melanoma, respectively. Cells were transfected with FKBP51 siRNA or a NS RNA as a control. Figure 2 shows reduced levels of pPKC in FKBP51 depleted melanoma.


Figure 1: Proteins differentially expressed in the FKBP51 silenced melanoma cells. (Upper) Top ten most significant pathways from GeneGo MetaCore analysis. (Lower) A map of EGFR signaling pathway: proteins on the map are indicated by different symbols representing the functional class of the protein reported in the legend. Red thermometers show increase in expression and blue decrease in expression, in FKBP51 depleted cells.


Figure 2: FKBP51 downmodulation of melanoma reduces levels of active PKC. Western blot assay of pPKC and FKBP51 levels in cell lysates obtained from two different melanoma cell lines, transfected with a specific FKBP51 siRNA, or a non-silencing (NS) RNA as control. Cell was harvested after 24 h from transfection, for lysate preparation.

Enzastaurin increases sensitivity of melanoma to IR-induced cell death

Because PKC activity was found decreased in FKBP51-silenced melanoma, and because FKBP51-silenced melanoma is radiosensitive [5], we investigated whether enzastaurin, a PKC inhibitor, could increase IR cytotoxicity in melanoma. For this reason, we analyzed the effect of enzastaurin on IR-induced cell death by annexin-V staining. We found that neither IR, or enzastaurin, as single agents, significantly enhanced melanoma cell death (Figure 3A). Differently, annexin-V positive cells were significant increased by the combination of enzastaurin and IR, in comparison to untreated cells or cells subjected to IR alone. These results suggested a sensitizing action of enzastaurin on IR cytotoxicity. Measure of caspase 3 activation, by flow cytometry, showed an increase of the active caspase in enzastaurin + IR sample, suggesting that cells died, at least in part, by apoptosis (Figure 3B).


Figure 3: Cooperative effect of enzastaurin and ionizing radiation in inducing melanoma cell death. A: Graphic representation of cell death values (columns are means and bars standard deviations) of SAN melanoma cells. Cells were irradiated with a 4 Gy dose and incubated in the absence or the presence of 0.6 μM and 2 μM enzastaurin for 48 h. Cell death was measured by annexin-V staining. Data were obtained from three independent experiments, each performed in triplicate. B: Flow cytometric histograms of active Caspase 3, of SAN melanoma cells treated with 4 Gy IR and/or 2 μM enzastaurin. Cells were harvested after 6h to measure caspase activity. Result is representative of two independent experiments.

We then investigated whether an additive effect could be measured using FKBP51 knock down and enzastaurin. Interestingly, we found that enzastaurin was able to kill melanoma cells in the absence of IR, in condition of FKBP51 depletion (Figure 4). This suggested that FKBP51-silencing inhibits further survival pathways in addition to that PKC-driven, which is consistent with previous studies [5-7]. According to these findings, enzastaurin, per se, can activate the melanoma apoptotic machinery, following FKBP51 knockdown.


Figure 4: FKBP51 knock down promotes enzastaurin citotoxicity of melanoma. A: Graphic representation of cell death values (columns are means and bars standard deviations) of SAN melanoma cells. Cells were transfected with a specific siRNA for FKBP51 and a NS RNA as control, irradiated with a 4 Gy dose and incubated in the absence or the presence of 0.6 μM enzastaurin for 48 h. Cell death was measured by annexin-V staining. Data were obtained from three independent experiments, each performed in triplicate.

Since radiocurability of a tumour implicates that the cancer stem/ initiating cell is killed [17], we investigated the effect of the association IR and enzastaurin on the viability of melanoma cancer stem/initiating cell. For this experiment, we thought to use A375 melanoma cell line, that in previous studies was shown to be more aggressive than SAN [14,18]. Melanoma cells, irradiated or not, and cultivated in the absence or the presence of enzastaurin, were harvested after 72 h and stained with ABCG2 monoclonal antibody. It is noted that ABCG2 belongs to the family of ATP-binding cassette transporters, which was demonstrated to be a marker of cells capable of recapitulating melanomas [19]. The number of ABCG2+ cells was calculated by flow cytometry. A gate was placed on live cells based on FSC/SSC physical parameters, and ABCG2 count was expressed as the number of positive cells/104 total cells. A result representative of four different experiments is shown in the Figure 5. Interestingly, we found that ABCG2+ cells were even increased in irradiated cultures, suggesting that IR killed ABCG2- cells, thus producing an enrichment of ABCG2+ in the remaining cells; or, as recently hypothesized in an in vivo model of glioblastoma [20], that a transition stimulus towards a stem like phenotype is induced by IR. Interestingly, the ABCG2+ subset was significantly reduced after combination treatment of enzastaurin with IR, suggesting such an association was suitable for eliminating cancer stem cells. To address this issue, we irradiated SAN and A375 melanoma cells with a 4 Gy dose and, after a 16 h and a 36 h incubation, cell was harvested, and RNA extracted. The levels of the transcript of several genes involved in cancer stemness, namely ABCG2 [15], HES1 [21], HEY [21], Jagged [22], Nestin [15], and OCT 4 [22] was measured by QPCR. Results of two different experiments are represented in Figure 6. In accordance with results of Leder et al [20], we found an increased expression of some stemness-related genes after IR, particularly, ABCG2 increased expression was consistent with the enhanced ABCG2+ population in irradiated melanoma.


Figure 5: Enzastaurin reduced number of ABCG2+ cells in irradiated cultures. Graphic representation of ABCG2+ cell counts in A375 melanoma cultures, irradiated or not with a 4 Gy dose and incubated in the absence or the presence of 2 μM enzastaurin. After 72 h, cells were harvested, stained with anti-ABCG2-PE and acquired with a flow cytometer. A gate was placed on live cells on the basis of the physical parameters FSC/SSC; the number of ABCG2+ cells was calculated and expressed as number of positive cells/104 total cells. Data were obtained from four different experiments, each performed in triplicate.


Figure 6: Effect of ionizing radiation on expression of stemness genes in melanoma. Graphic representation of relative normalized expression rates (means and standard deviations) of IR-regulated stemness genes. A375 (upper panel) and SAN (lower panel) melanoma cells, were irradiated or not with a 4 Gy dose, and harvested after 16 h and 36 h. Unirradiated sample was arbitrarily used as reference sample (expression=1). GAPDH was used as internal control of amplification.


Therapy of advanced stage melanoma constitutes a difficult task for the oncologists. Although recent advances in bio- and immunotherapy have substantially improved the outcome of a significant portion of such patient population, most of the patients experience a rapid evolution of the disease and a short survival time.

Radiation therapy is one of the tools usefully employed in the treatment of melanoma patients, despite melanoma is considered one of the less radiation sensitive neoplasms. The limitations of RT, as well as of the conventional cytotoxic drugs, in melanoma, are due to an inherent resistance to genotoxic agents of a portion of the cellular population. An interesting report by Sambade et al. [23], indeed, shows that among 37 melanoma cell lines there is a very wide range of sensitivity. On average, melanoma cell lines are not less sensitive than other cell lines of cancers (i.e. breast cancer and lung cancer) for which RT plays a major role in the cure of disease. Furthermore, the same study indicated that, although B-Raf inhibitors potentiate the effect of RT on B-Raf mutated melanoma cells, B-Raf and N-Ras mutational status are not associated with the response to ionizing radiation [23]. Thus the definition of the molecular mechanisms involved in radioresistance may suggest new druggable targets for combination therapy aimed at ameliorating the outcome of this disease. In this frame, our proteomic study discloses the molecular alterations able to modify the response to ionizing radiation.

On the basis of previous studies showing that FKBP51 is involved in radioresistance of melanoma, we focused our attention on the molecular changes caused by the silencing of this gene in our melanoma model. Array based proteomics are routinely employed for differential proteomics studies and quantification and validation of regulated proteins, biomarkers and targets. By this approach we obtained results that are in line with previous studies, which underlines the reliability of this technology. A signal transduction map constructed with data of protein profiles, supported previous findings that FKBP51 regulated pathways related to apoptosis [5-7,24], TGF-β signaling [15,18], immune response [25], NF-κB activation [5-7,26-28], neuronal death and survival [29-31] and epithelial to mesenchymal transition [15,18]. The finding of reduced levels of several pPKC isoforms in FKBP51- depleted IR sensitive melanoma is consistent with the notion that PKC is one of the earliest responders to IR. PKC has been shown to be involved in radiation resistance in different cellular systems [32,33], and its inhibition increases the cell killing by IR [10-12]. Enzastaurin, or LY317615, is a synthetic bisindolylmaleimide drug developed by Eli Lilly. It has been shown to be effective especially in combination with genotoxic drugs, including melphalan and doxorubicin [33,34]. Previous studies support the efficacy of this agent in malignant melanoma [14,35]. Consistent with previous findings [5,36,37], ionizing radiation produces only a slight effect on melanoma cell death. Treatment of melanoma with enzastaurin produced a significant increase in IR-induced cytotoxicity, which was accompanied by caspase 3 activation, suggesting the involvement of apoptosis machinery in the increased response to IR. Most interestingly, the cooperative effect between enzastaurin and IR appeared to be effective in reducing the counts of melanoma cells expressing the stem cell marker ABCG2. For radiotherapy treated cancers, as well as glioma and melanoma, it has been hypothesized that the tumour consists of two separate populations of cells: the largely radioresistant stem-like cells and the radiosensitive differentiated cells. This model hypothesizes that, after exposure to radiation, a fraction of the radiosensitive cells could rapidly revert to the radioresistant state, becoming capable of repopulation during the treatment period and recovery from radiation damage [20]. In this context, the finding that enzastaurin is able to reduce the number of ABCG2+ melanoma cells, with cancer stem cell features [15] could be of particular interest for the therapy of this neoplasm. In conclusion, our study supports the hypothesis that enzastaurin is a promising melanoma radiosensitizing agent that deserves to be investigated in a clinical setting.


We thanks the Cardiovascular Service srl for supporting this research.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 9th International Conference on Bioinformatics
    October 23-24, 2017 Paris, France
  • 9th International Conference and Expo on Proteomics
    October 23-25, 2017 Paris, France

Article Usage

  • Total views: 11643
  • [From(publication date):
    August-2014 - Sep 22, 2017]
  • Breakdown by view type
  • HTML page views : 7878
  • PDF downloads :3765

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version